03-28-2001 FORM PTO-1619A U.S. Department of Comm Entries 04/30/00 OMB 0851-0027 Patent and Trademark Office **PATENT** 101651063 **RECORDATION FORM COVER SHEET** 146.1357 PATENTS ONLY TO: The Commissioner of Patents and Trademarks: Please record the attached original document(s) or copy(ies). **Submission Type** Conveyance Type New **Assignment Security Agreement** Resubmission (Non-Recordation) License Document ID# Change of Name Correction of PTO Error Merger Other Reel # Frame # U.S. Government
(For Use ONLY by U.S. Government Agencies) Corrective Document Reel # Frame # Departmental File Secret File Conveying Party(ies) Mark if additional names of conveying parties attached Execution Date Name (line 1) GADAK, THOMAS Month Day 31 01 01 Name (line z) Second Party Execution Date Month Day Name (line 1) BODARY, SARAH CATHERINE 02 14 01 Name (line 2) **Receiving Party** Mark if additional names of receiving parties attached Name (time 1) | AVENTIS PHARMA DEUTSCHLAND GMBH If document to be recorded is an assignment and the receiving party is not Name (line 2) GENENTECH INC. domiciled in the United States, an appointment of a domestic Address (Gine 1) Bruningstrasse 50, D-65929 Frankfurt am Main, Germany representative is attached. (Designation must be a separate document from Address (line 2) [1 DNA Way, South San Francisco, CA 94080-4990 U.S.A. Assignment) Address (line 3) State/Country Domestic Representative Name and Address Enter for the first Receiving Party only. Name 40.00 BP 06 FC:581 Address (line 1) Address (line 2) Address (line 3) Address (line 4) FOR OFFICE USE ONLY

Public burden reporting for this collection of information is estimated to average approximately 30 minutes per Cover Sheet to be recorded, including time for reviewing the document and gathering the data needed to complete the Cover Sheet. Send comments regarding this burden estimate to the U.S. Patent and Trademark Office, Chief Information Officer, Washington, D.C. 20231 and to the Office of Information and Regulatory Affairs, Office of Management and Budget, Paperwork Reduction Project (0651-0027), Washington, D.C. 20503. See OMB Information Collection Budget Package 8651-0027, Patent and Trademark Assignment Practice. DO NOT SEND REQUESTS TO RECORD ASSIGNMENT DOCUMENTS TO THIS ADDRESS.

Mail documents to be recorded with required cover sheet(s) information to: Commissioner of Patents and Trademarks, Box Assignments , Washington, D.C. 20231

> PATENT REEL: 011614 FRAME: 0370

FORM PTO Expires 00/0009 OMB 0051-0027)-1619B 146. 1 357	Page 2	U.S. Department of Commerce Patent and Trademark Office PATENT				
Correspond	ent Name and Address	Area Code and Telephone Number 212	661-8000				
Name	Charles A. Muserlian						
Address (line 1)	Bierman, Muserlian and	Lucas, 600 Third Ave, N.Y., N.Y.	10016				
Address (line 2)							
Address (line 1)							
Address (line 4)							
Pages	Enter the total number of pagincluding any attachments.	ges of the attached conveyance document	# 5				
• •	Number(s) or Patent Num	Ld	nal numbers attached				
		atent Number (DO NOT ENTER BOTH numbers for the Patent Num					
09/700,65	tent Application Number(s)						
		de de la participa Vicini	Month Day Year				
If this document signed by the fir	is being filed together with a new Pater st named executing inventor.	x Application, enter the date the patent application was					
	peration Treaty (PCT)	PCT PCT	PCT				
Ent	er PCT application number y if a U.S. Application Number	PCT PCT	PCT				
oni has	s not been assigned.	PCT PCT					
Number of	Properties Enter the tot	al number of properties involved. # 1					
Fee Amoun	it Fee Amount	for Properties Listed (37 CFR 3.41): \$ 4	0.00				
	d of Payment: Enclo		Form-2038 enclosed.				
1 -	it Account	itional fees can be charged to the account.)	2-2275				
(2	ı	Deposit Account Number.	s V No C				
		Authorization to charge additional fees: Ye	s X 10				
Statement	and Signature						
To the best of my knowledge and belief, the foregoing information is true and correct and any attached copy is a true copy of the original document. Charges to deposit account are authorized, as							
indic	cated herein.		March 6, 2001				
Charles	S A. Muserlian me of Person Signing	Signature	Date				
Mar	He of the name of Drugs						

PATENT REEL: 011614 FRAME: 0371

146.1357

ASSIGNMENT OF APPLICATION FOR PATENT

WHEREAS, WE, K.H. SCHEUNEMANN, J. KNOLLE, A. PEYMAN, D.W. WILL, D. CARNIATO, J.F. GOURVEST, T. GADEK, R. MCDOWELL, S.C. BODARY and R.A. CUTHBERTSON citizens of Germany, Germany, Germany, Unite Kingdom, France, France, U.S.A., U.S.A., U.S.A. and Australia, respectively, and residents of Germany, Germany, Germany, Germany, France, France, U.S.A., U.S.A., U.S.A. and Australia, respectively, for which Application PCT/EP99/03064 has been filed on May 5, 1999 in which the United States has been named as a Designated State, and an application for Letters Patent of the United States thus entitled has been made, said application having been executed on even date herewith and the European priority date of May 19, 1998 of Application Serial No. 98109077.2 is hereby claimed.

whereas, <u>Aventis Pharma Deutschland Gmbh and Genentech Inc.</u> corporations duly organized and existing under the laws of <u>Germany</u> and the <u>United States</u> and having a place of business at <u>Bruningstrasse 50, D-65929 Frankfurt am Main, Germany and 1 DNA Way, South San Francisco, CA 94080-4990, U.S.A. are desirous of acquiring the entire right, title and interest in and to said invention, application and any Letters Patent which may issue thereon;</u>

NOW, THEREFORE, to all whom it may concern, be it known that we, the said K.H. SCHEUNEMANN, J. KNOLLE, A. PEYMAN, D.W. WILL, D. CARNIATO, J.F. GOURVEST, T. GADEK, R. MCDOWELL, S.C. BODARY and R.A. CUTHBERTSON for and in consideration of the sum of ONE DOLLAR (\$1.00) to us in hand paid by the said AVENTIS PHARMA DEUTSCHLAND

PATENT REEL: 011614 FRAME: 0372 GMBH AND GENENTECH INC. and for other good and valuable considerations, the receipt of all of which is hereby acknowledged, do hereby sell, assign, transfer and set over unto the said AVENTIS PHARMA DEUTSCHLAND GMBH AND GENENTECH INC. its successors and assigns, the entire right, title and interest in and to said invention, said application and any Letters Patent that may issue thereon in the United States together with any division or divisions, extension or extensions, reissue or reissues thereof;

AND, We hereby authorize and request the Commissioner of Patents and Trademarks to issue any and all Letters Patent which may issue upon said invention to said <u>AVENTIS PHARMA DEUTSCHLAND</u> <u>GMBH AND GENENTECH INC.</u> as assignee of the entire right, title and interest in and to said invention, application and any Letters Patent that may issue thereupon.

IN WITNESS WHEREOF, We have hereunto set our hands as of the following date:

	Date:
KARL HEINZ SCHEUNEMANN	
	Date:
JOCHEN KNOLLE	
	Date:
ANUSCHIRWAN PEYMAN	
	Date:
DAVID WILLIAM WILL	
	Date:
DENIS CARNIATO	
	Date:
JEAN-FRANCOIS GOURVEST	

2

THOMAS GADEK	~	Date:	1/3/1/2001	
ROBERT MCDOWELL		Date:		
SARAH CATHERINE BODARY		Date:	2.14.200	
ROBERT ANDREW CUBERTSON		Date:		
	: : S :	S:		
On this	day c	f	-10	before
me personally came				
to me know and known to m	me to be	the in	dividuals described	in and
who executed the foregoir	ng instr	ument a	nd fully acknowledge	ed that
they executed the same.				

RECORDED: 03/06/2001